Related Experiment Video
Updated: Feb 11, 2026

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal
Published on: January 26, 2019
PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression
Yi-Zi Zheng1,2, Meng-Zhu Xue3, Hong-Jie Shen4
1Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Abstract:
Alternative splicing (AS) and its regulation play critical roles in cancer, yet the dysregulation of AS and its molecular bases in breast cancer development have not yet been elucidated. Using an in vivo CRISPR screen targeting RNA-binding proteins, we identified PHD finger protein 5A (PHF5A) as a key splicing factor involved in tumor progression. PHF5A expression was frequently upregulated in breast cancer and correlated with poor survival, and knockdown of PHF5A significantly suppressed cell proliferation, migration, and tumor formation. PHF5A was required for SF3b spliceosome stability and linked the complex to histones, and the PHF5A-SF3b complex modulated AS changes in apoptotic signaling. In addition, expression of a short truncated FAS-activated serine/threonine kinase (FASTK) protein was increased after PHF5A ablation and facilitated Fas-mediated apoptosis. This PHF5A-modulated FASTK-AS axis was widely present in breast cancer specimens, particularly those of the triple-negative subtype. Taken together, our findings reveal that PHF5A serves as an epigenetic suppressor of apoptosis and thus provides a mechanistic basis for breast cancer progression and may be a valuable therapeutic target.Significance: This study provides an epigenetic mechanistic basis for the aggressive biology of breast cancer and identifies a translatable therapeutic target. Cancer Res; 78(12); 3190-206. ©2018 AACR.
Insights
PHD finger protein 5A (PHF5A) promotes breast cancer by suppressing apoptosis. Targeting PHF5A may offer a new therapeutic strategy for aggressive breast cancers, including triple-negative subtypes.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Alternative splicing (AS) dysregulation is crucial in cancer, but its role in breast cancer remains unclear.
- RNA-binding proteins are key regulators of AS, influencing tumor development.
- Identifying specific splicing factors involved in breast cancer progression is essential.
Purpose of the Study:
- To investigate the role of RNA-binding proteins in breast cancer development.
- To identify key splicing factors contributing to breast cancer progression.
- To elucidate the molecular mechanisms underlying PHF5A's function in breast cancer.
Main Methods:
- Conducted an in vivo CRISPR screen targeting RNA-binding proteins.
- Assessed PHF5A expression in breast cancer specimens.
- Performed knockdown experiments to evaluate PHF5A's functional impact.
- Investigated the interaction of PHF5A with the SF3b spliceosome and histones.
- Analyzed the PHF5A-FASTK axis in breast cancer samples.
Main Results:
- PHD finger protein 5A (PHF5A) was identified as a critical splicing factor in breast cancer.
- PHF5A is upregulated in breast cancer, correlating with poor survival.
- PHF5A knockdown suppressed tumor cell proliferation, migration, and formation.
- PHF5A stabilizes the SF3b spliceosome and influences alternative splicing of apoptotic genes.
- PHF5A ablation increased truncated FASTK, enhancing Fas-mediated apoptosis.
Conclusions:
- PHF5A acts as an epigenetic suppressor of apoptosis, driving breast cancer progression.
- The PHF5A-modulated FASTK-AS axis is prevalent in breast cancer, especially triple-negative subtypes.
- PHF5A represents a potential therapeutic target for breast cancer treatment.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Eukaryotic Promoter Region
Apoptosis
Feedback Inhibition

